How to Get Prometrium in Indiana

Who Can Prescribe Prometrium in Indiana

Any Indiana-licensed physician (MD or DO) may prescribe Prometrium without restriction. Nurse practitioners and physician assistants can also prescribe it, though Indiana law requires NPs to maintain a collaborative practice agreement with a physician. This agreement does not limit the NP's ability to prescribe Schedule V or unscheduled medications like micronized progesterone; it simply establishes a supervisory framework.

PAs in Indiana prescribe under a supervisory agreement with a physician as well. In practice, this means the vast majority of primary care, OB-GYN, and endocrinology clinicians in the state can write a Prometrium prescription during an office visit or telehealth encounter.

The PEPI trial (Postmenopausal Estrogen/Progestin Interventions, N=875) established that micronized progesterone at 200 mg/day for 12 days per cycle provided endometrial protection comparable to medroxyprogesterone acetate (MPA) while producing a more favorable lipid profile. HDL cholesterol increased by 4.1 mg/dL in the micronized progesterone group versus a 2.4 mg/dL decrease in the MPA group (1). That trial remains the clinical foundation for Prometrium's role in combined HRT regimens. Prescribers in Indiana typically reference these data when selecting micronized progesterone over synthetic progestins.

Telehealth Access to Prometrium in Indiana

Indiana permits telehealth prescribing for non-controlled medications, and Prometrium falls squarely in that category. A patient in Indianapolis, Fort Wayne, or rural Vanderburgh County can consult a licensed prescriber via synchronous video and receive a prescription sent electronically to any Indiana pharmacy.

Several national telehealth platforms and Indiana-based hormone therapy clinics offer consultations specifically for HRT management. The typical workflow: schedule a video visit, upload recent lab results (or order labs through the platform), and receive a prescription within 24 to 72 hours of the clinical review. No in-person visit is required for the initial prescription in most cases, though some clinicians prefer an in-person baseline exam for patients new to hormone therapy.

The Endocrine Society's 2022 clinical practice guidelines recommend that postmenopausal women with an intact uterus who receive systemic estrogen therapy should also receive progestogen therapy to prevent endometrial hyperplasia (2). This guideline applies regardless of whether the prescription originates from a telehealth or in-person encounter.

One consideration specific to Indiana: the state does not impose a separate telehealth-specific license requirement. Any clinician licensed in Indiana may provide telehealth services to patients located in the state. Out-of-state providers, though, must hold an Indiana medical license or qualify under the Interstate Medical Licensure Compact, which Indiana joined in 2018.

Indiana Medicaid and Insurance Coverage

This is where Indiana patients face a real barrier. Indiana Medicaid (including the Healthy Indiana Plan, HIP 2.0) does not cover Prometrium for its FDA-approved indication of endometrial protection during HRT. Coverage is restricted to type 2 diabetes-related indications only, a narrow formulary decision that leaves many postmenopausal women without Medicaid coverage for this drug.

For patients on Indiana Medicaid who need progesterone for endometrial protection, the options are limited. The prescriber can submit a prior authorization request, but approval rates for off-formulary HRT indications under Indiana Medicaid are low. Documentation required for a prior authorization attempt typically includes:

• A letter of medical necessity from the prescribing clinician
• Lab results confirming menopausal status (FSH >30 mIU/mL, estradiol levels)
• Documentation of the concurrent estrogen prescription
• Clinical rationale for micronized progesterone over synthetic alternatives (if a synthetic progestin is on formulary)

Commercial insurers in Indiana generally cover brand-name Prometrium on a Tier 2 or Tier 3 formulary position. Generic micronized progesterone capsules sit on Tier 1 at most commercial plans, with copays ranging from $5 to $25 for a 30-day supply. The FDA Orange Book lists multiple approved ANDA generics for micronized progesterone 100 mg and 200 mg capsules (3).

Without insurance, cash-pay pricing for generic micronized progesterone runs $20 to $60 for a 30-day supply at major chain pharmacies in Indiana. Brand-name Prometrium is significantly more expensive, typically $200 to $350 without a discount card.

503A Compounding Pharmacies in Indiana

Indiana licenses 503A compounding pharmacies under the Indiana Board of Pharmacy, and these pharmacies can prepare micronized progesterone in custom formulations. This matters for patients who need a dose or delivery form not available commercially, such as vaginal suppositories, topical creams, or sublingual troches.

A 503A pharmacy compounds medications pursuant to a patient-specific prescription from a licensed prescriber. Indiana 503A pharmacies can ship compounded progesterone to patients within the state. Some also ship to other states where their pharmacy holds a nonresident license.

The key regulatory distinction: 503A compounding pharmacies operate under state pharmacy board oversight and Section 503A of the Federal Food, Drug, and Cosmetic Act (4). They must compound from bulk pharmaceutical-grade ingredients, and they cannot manufacture drugs in anticipation of receiving prescriptions (no "batch" compounding for general distribution). For patients who tolerate the commercially available Prometrium capsule, the brand or generic product is typically preferable because it has undergone FDA bioequivalence testing.

Compounded micronized progesterone may cost $30 to $80 per month depending on the formulation and pharmacy, though pricing varies widely. Patients in the Indianapolis, Carmel, and Fishers corridor have access to several compounding pharmacies; options are more limited in rural southern Indiana, though mail-order from licensed 503A pharmacies addresses that gap.

Labs Required Before Starting Prometrium in Indiana

Before prescribing Prometrium, clinicians in Indiana follow standard clinical protocols that include baseline laboratory evaluation. The specific panel varies by practice, but a typical pre-prescription workup includes:

Hormone levels. Serum progesterone, estradiol, FSH, and LH. These confirm menopausal status and establish a baseline for monitoring. FSH levels above 30 mIU/mL with estradiol below 30 pg/mL are consistent with menopause in women over 45 (5).

Hepatic function. Prometrium is metabolized by the liver, and the FDA label carries a precaution regarding hepatic impairment. AST, ALT, and bilirubin should be within normal limits before initiation.

Lipid panel. The PEPI trial demonstrated that micronized progesterone has a neutral-to-favorable effect on lipids compared to MPA, but baseline lipids help guide overall cardiovascular risk assessment during HRT (1).

CBC. A complete blood count screens for anemia, which can confound symptom assessment in perimenopausal and postmenopausal women.

Endometrial thickness. Transvaginal ultrasound may be ordered if a patient reports abnormal uterine bleeding before starting therapy. An endometrial stripe >4 mm in a postmenopausal woman warrants further evaluation before adding progesterone (6).

Lab orders can be placed through telehealth platforms and completed at any Quest Diagnostics, Labcorp, or hospital lab in Indiana. Results are typically available within 2 to 5 business days.

How Long Until You Receive Prometrium in Indiana

Timeline depends on the prescribing pathway. A realistic breakdown:

Telehealth route. Scheduling a consultation takes 1 to 3 days. If labs are already available, a prescription can be sent the same day as the visit. Pharmacy fill time at a retail pharmacy is typically same-day or next-day. Total: 2 to 5 days from initial appointment scheduling to medication in hand.

In-person visit. Scheduling with an OB-GYN or endocrinologist in Indiana may take 2 to 6 weeks depending on location and provider availability. Once seen, the prescription process is the same. Fort Wayne and Indianapolis have shorter wait times than rural areas.

503A compounding. Add 3 to 7 business days for compounding and shipping after the pharmacy receives the prescription. Some pharmacies offer expedited compounding for an additional fee.

Prior authorization (if required). Commercial insurance prior authorizations in Indiana typically resolve within 3 to 5 business days. Medicaid prior authorizations can take up to 14 business days, and the approval rate for HRT-indication Prometrium is low as noted above.

The American College of Obstetricians and Gynecologists (ACOG) recommends that women initiating combined estrogen-progestogen therapy should begin progestogen at the same time as estrogen, not weeks later, to avoid any window of unopposed estrogen exposure to the endometrium (7).

Transferring a Prometrium Prescription to Indiana

Patients relocating to Indiana or visiting for an extended period can transfer an existing Prometrium prescription from another state. Indiana Board of Pharmacy regulations allow prescription transfers for non-controlled substances between pharmacies.

The process is straightforward. Call the receiving Indiana pharmacy, provide the details of the originating pharmacy, and the pharmacist will initiate the transfer. Electronic prescriptions can also be canceled at the original pharmacy and re-sent to an Indiana pharmacy by the prescriber. Refills remaining on the original prescription transfer with it.

For patients using a national chain (CVS, Walgreens, Kroger), the transfer may be even simpler, as these chains often allow intra-chain transfers through their internal systems. Patients using a 503A compounding pharmacy will need their prescriber to send a new prescription to the Indiana compounding pharmacy, as compounded prescriptions do not transfer in the same way.

Prometrium Dosing and Clinical Considerations

The FDA-approved dosing for endometrial protection is 200 mg orally at bedtime for 12 consecutive days per 28-day cycle when used with conjugated estrogens (3). Continuous combined regimens use 100 mg nightly. The bedtime dosing is deliberate: micronized progesterone produces a metabolite (allopregnanolone) with sedative properties, which can cause drowsiness.

Peanut allergy is a specific contraindication for Prometrium capsules. The branded product contains peanut oil as a suspending agent. Patients with confirmed peanut allergy should use a compounded micronized progesterone formulation that substitutes a different oil base, or switch to a non-oral route. This is one of the most common clinical reasons for utilizing a 503A compounding pharmacy in Indiana.

The Women's Health Initiative (WHI) found that the combination of conjugated equine estrogens plus MPA increased breast cancer risk (HR 1.26 to 95% CI 1.00-1.59) over 5.6 years of follow-up (8). Observational data from the French E3N cohort (N=80,377) suggest that micronized progesterone may carry a lower breast cancer risk than synthetic progestins, with no significant increase in breast cancer risk over 8 years of use (RR 1.00 to 95% CI 0.83-1.22) (9). These data have driven a preference for micronized progesterone among many HRT prescribers in Indiana and nationally.

Cost Comparison: Brand vs. Generic vs. Compounded in Indiana

Pricing transparency matters for Indiana patients navigating a drug that Medicaid may not cover. Based on 2026 retail pricing:

• Generic micronized progesterone 200 mg, 30 capsules: $20-$45 at Kroger, CVS, and Walgreens locations in Indiana
• Brand Prometrium 200 mg, 30 capsules: $200-$350 without insurance
• Compounded micronized progesterone 200 mg oral capsules: $30-$80 at Indiana 503A pharmacies
• Compounded vaginal suppositories (200 mg, 30 count): $40-$90

Generic oral capsules represent the lowest-cost option for most patients. The AbbVie patient assistance program may help uninsured or underinsured patients access brand Prometrium, though eligibility criteria apply and Medicaid recipients are typically excluded from manufacturer assistance programs.